DE1695043A1 - Chemical compounds and compositions - Google Patents

Chemical compounds and compositions

Info

Publication number
DE1695043A1
DE1695043A1 DE19671695043 DE1695043A DE1695043A1 DE 1695043 A1 DE1695043 A1 DE 1695043A1 DE 19671695043 DE19671695043 DE 19671695043 DE 1695043 A DE1695043 A DE 1695043A DE 1695043 A1 DE1695043 A1 DE 1695043A1
Authority
DE
Germany
Prior art keywords
compound
formula
group
compounds
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19671695043
Other languages
German (de)
Other versions
DE1695043C2 (en
Inventor
Phillipe Gold-Aubert
Diran Melkonian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOLD AUBERT PHILLIPE
Original Assignee
GOLD AUBERT PHILLIPE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOLD AUBERT PHILLIPE filed Critical GOLD AUBERT PHILLIPE
Publication of DE1695043A1 publication Critical patent/DE1695043A1/en
Application granted granted Critical
Publication of DE1695043C2 publication Critical patent/DE1695043C2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

P a t e η t a ns ρ r ü c h eP a t e η t a ns ρ r ü c h e 1. "Verbindungen der allgemeinen !Formel1. "Compounds of the general! Formula OO ET _ E5 OO ET _ E 5 COCO in der E und E , die gleich oder verschieden sein können, Wasserstoffatome oder aliphatische, araliphatisch^ oder · Arylgruppen, wie beispielsweise Alkyl- oder Alkenylgruppen,in the E and E, which can be the same or different, Hydrogen atoms or aliphatic, araliphatic ^ or Aryl groups, such as alkyl or alkenyl groups, ■χ κ
und Έγ und E , die gleich oder verschieden sein können, aliphatische Gruppen, deren jede mindestens eine Oarbamyloxy- ■ χ κ
and Έγ and E, which can be the same or different, are aliphatic groups, each of which has at least one Oarbamyloxy- Ί 2Ί 2 gruppe trägt, bedeuten, wobei E und/oder E insbesondere Allyl- oder Phenylgruppen. oder Alkylgruppen mit 1 bis Kohlenstoffatomen, wie beispielsweise Ithyl- oder Isopentylgruppen, bedeuten können.group carries, mean, where E and / or E in particular Allyl or phenyl groups. or alkyl groups with 1 to carbon atoms, such as ethyl or isopentyl groups, can mean. 2. Verbindungen gemäß Anspruch 1, dadurch gekennzeichnet, daß E^ oder E eine Propylgruppe bedeutet, die unsubstituiert oder durch eine n-Butoxygruppe substituiert ist.2. Compounds according to claim 1, characterized in that that E ^ or E is a propyl group which is unsubstituted or is substituted by an n-butoxy group. 3. "Verbindungen gemäß Anspruch 1, dadurch gekennzeichnet3. "Compounds according to claim 1, characterized Vorr. nc.'f- «-5-r-. P-ohr v·. " .Vorr. Nc.'f- «-5-r-. P-ohr v ·. ". nichtnot 2098 18/11592098 18/1159 3 4
daß E^ und R gleich sind und die Gruppe3 4
that E ^ and R are the same and the group 0-GO-NH2 0-GO-NH 2 bedeuten.mean. 4·. N,Fl-Di-(2-carl)ainyloxy-3-"butox7-propyl)-phenobarbital.4 ·. N, F l -di (2-carl) ainyloxy-3 "butox7-propyl) phenobarbital. 5. n,N'-Di-(2-carbamyloxy-3-butoxy-propyl)-veronal.5. n, N'-di (2-carbamyloxy-3-butoxy-propyl) -veronal. 6. Pharmazeutische Zusammensetzungen, dadurch gekennzeichnet, daß sie mindestens eine Verbindung der in Anspruch 1 definierten Formel I zusammen mit mindestens einer Verbindung der allgemeinen Formel6. Pharmaceutical compositions, characterized in that that they contain at least one compound of those defined in claim 1 Formula I together with at least one compound of the general formula ,CO-N-E5 E1 v .CO-EH, CO-NE 5 E 1 by .CO-EH C CO oderC CO or ^CO-NH E^ J11 CO-NH^ CO-NH E ^ J 11 CO-NH in der E , E und E^ die in Anspruch 1 angegebenen Bedeutungen besitzen, enthalten.in which E, E and E ^ the meanings given in claim 1 own, contain. 7. Zusammensetzungen gemäß Anspruch 6, dadurch gekennzeichnet, daß sie mindestens eine Verbindung der Formel II und mindestens eine Verbindung der Formel IEI, wie in Anspruch 6 definiert, enthalten.7. Compositions according to claim 6, characterized in that they contain at least one compound of formula II and at least one compound of the formula IEI as in claim 6 defined, included. Vom D;v.«: -.·-,' ■:--, ;■■>-. -,•r.ni^m.t
ohr:ν. "■ ■ . .-r.-.g^ Vom D; v. «: -. · -, '■: -,; ■■> -. -, • r.ni ^ mt
ear: ν. "■ ■..- R .-. G ^ 'Λ '-: ■ · — ^St 'Λ' -: ■ · - ^ St —-.1 -jCs«—-. 1 -jCs « 209818/1159209818/1159 8. Zusammensetzungen gemäß Anspruch. 7» dadurch gekennzeichnet, daß sie 30 - 45 Gew.-% einer Verbindung der Formel I, 40-60 Gew.-% einer Verbindung der Formel II und 10 - 20 Gew.-% einer Verbindung der Formel III enthalten.8. Compositions according to claim. 7 »characterized by that they are 30-45% by weight of a compound of Formula I, 40-60% by weight of a compound of the formula II and 10-20% by weight of a compound of the formula III. 9. Pharmazeutische Zusammensetzungen, dadurch gekennzeichnet, daß sie mindestens eine Verbindung der in Anspruch 1 definierten Formel I zusammen mit einem pharmazeutischen Träger- oder Hilfsstoff enthalten.9. Pharmaceutical compositions, characterized in that that they contain at least one compound of the formula I defined in claim 1 together with a pharmaceutical Contain carrier or excipient. 10. Verfahren zur Herstellung der in Anspruch 1 definierten10. A process for the preparation of those defined in claim 1 ' 4'4 Verbindungen, dadurch gekennzeichnet, daß eine Gruppe R in das unsubstituierte Stickstoffatom einer Verbindung der FormelCompounds, characterized in that a group R is in the unsubstituted nitrogen atom of a compound of the formula 11. wie sie in Anspruch 6 definiert ist, eingeführt wird.11. as defined in claim 6 is introduced. 11. Verfahren gemäß Anspruch 10, dadurch gekennzeichnet, daß ein Alkalimetallderivat der Verbindung der Formel II mit11. The method according to claim 10, characterized in that an alkali metal derivative of the compound of formula II with IlIl einer Verbindung der Formel HaI-R , in der Hai ein Halogen-a compound of the formula HaI-R, in which Hai is a halogen atom und R die in Anspruch 1 angegebene Bedeutung besitzt, umgesetzt wird.atom and R has the meaning given in claim 1, is implemented. 12. Verfahren gemäß Anspruch 11, dadurch gekennzeichnet, daß Hai ein Chlor-, Brom- oder Jodatom bedeutet und das Alkalimetall Natrium ist.12. The method according to claim 11, characterized in that Hai means a chlorine, bromine or iodine atom and that The alkali metal is sodium. 13. Verfahren zur Herstellung der in Anspruch 1 definierten Verbindungen, dadurch gekennzeichnet, daß R^ und R gleich13. A process for the preparation of those defined in claim 1 Compounds, characterized in that R ^ and R are the same sind, wobei ein Dialkalimetallderivat einer Verbindung der Vor :<?-■·i\- --h".-! r^c-nferntwhere a dialkali metal derivative of a compound removes the following: <? - ■ · i \ - --h ".-! r ^ c-n ε· . ■ ■ .; :©r- 2 0 9 8 18/1 159ε ·. ■ ■.; : © r- 2 0 9 8 18/1 159 r,;:-:.Vi. u;«;..Lv:i;U3 nichtr,;: - :. Vi. u; «; .. Lv: i; U3 not Formel III mit einer Verbindung der Formel HaI-R , wie in Anspruch 1 definiert, umgesetzt wird.Formula III with a compound of the formula Hal-R, such as defined in claim 1, is implemented. 14-. Verfahren gemäß einem der Ansprüche 10 bis 13, dadurch gekennzeichnet, daß zur Herstellung einer Mischung der Verbindungen I, II und III, wie sie in Anspruch 7 definiert ist, eine Mischung der Mono- und Dialkalimetallderivate einer Verbindung der Formel III mit einer Verbindung14-. Method according to one of Claims 10 to 13, characterized characterized in that for the preparation of a mixture of the compounds I, II and III as defined in claim 7 is a mixture of the mono- and dialkali metal derivatives a compound of the formula III with a compound Il -Il - der Formel HaI-R , wie in Anspruch 11 definiert, umgesetzt wird. ■of the formula Hal-R as defined in claim 11, implemented will. ■ 15· Verfahren gemäß einem der Ansprü-che 10 bis 14, dadurch15 · Method according to one of claims 10 to 14, characterized in that 1 21 2 gekennzeichnet, daß R eine Fhenylgruppe und R eine Äthylgruppe ist.characterized in that R is a fhenyl group and R is an ethyl group is. ■--·'■ Vi^^t^-^ciiJe nicht
nci Kind. ■ - · '■ Vi ^^ t ^ - ^ ciiJe not
nci child.
DE19671695043 1966-10-26 1967-10-26 Pharmaceutical compositions having sedative and tranquilizing properties Expired DE1695043C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4812066A GB1193438A (en) 1966-10-26 1966-10-26 Barbituric Acid Derivatives, preparation thereof and Pharmaceutical Compositions containing them

Publications (2)

Publication Number Publication Date
DE1695043A1 true DE1695043A1 (en) 1972-04-27
DE1695043C2 DE1695043C2 (en) 1983-02-17

Family

ID=10447466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19671695043 Expired DE1695043C2 (en) 1966-10-26 1967-10-26 Pharmaceutical compositions having sedative and tranquilizing properties

Country Status (8)

Country Link
AT (1) AT299238B (en)
BE (1) BE705672A (en)
CH (1) CH514595A (en)
DE (1) DE1695043C2 (en)
ES (1) ES346424A1 (en)
FR (2) FR1549453A (en)
GB (1) GB1193438A (en)
NL (1) NL6714587A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581834A (en) * 1976-11-01 1980-12-31 Sapos Sa Complexes of barbituric acid derivatives
GB8309813D0 (en) * 1983-04-12 1983-05-18 Sapos Sa Pyrimidinetrione derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rote Liste, Seiten 846 und 1190 (1965) *

Also Published As

Publication number Publication date
BE705672A (en) 1968-04-26
FR8022M (en) 1970-08-03
NL6714587A (en) 1968-04-29
CH514595A (en) 1971-10-31
ES346424A1 (en) 1969-04-16
FR1549453A (en) 1968-12-13
AT299238B (en) 1972-06-12
DE1695043C2 (en) 1983-02-17
GB1193438A (en) 1970-06-03

Similar Documents

Publication Publication Date Title
DE2615373A1 (en) PROCESS FOR IMPROVING THE POT LIFE OF POLYMERIZABLE EPOXIDE COMPOSITIONS
SE7407913L (en)
DE3010375A1 (en) FLAME RETARDANT, METHOD FOR THE PRODUCTION THEREOF AND FLAME RETARDANT RESIN
DE2728241A1 (en) COSMETIC LIGHT PROTECTION AGENTS FOR THE UV-A AREA
DE2005530B2 (en) Jumping putty
DE3009071C2 (en) 2-isopropylamino-hydroxypyrimidine compounds, processes for their preparation and pharmaceuticals containing these compounds
KR880012532A (en) Novel bicyclic compounds, preparation methods thereof, and pharmaceutical compositions comprising the compounds
ATE3636T1 (en) HEPTENO-NITRILES, PROCESS FOR THEIR PRODUCTION AND PERFUME COMPOSITIONS CONTAINING THEM.
DE1695043A1 (en) Chemical compounds and compositions
DE1695271A1 (en) Pest repellants
DE1770414A1 (en) Anilides of quinuclidine-2 and quiniclidine-3-carboxylic acid and process for their preparation
DE1618935A1 (en) N-mercaptophenyl fatty acid amides and processes for their preparation
DE73155T1 (en) ANTITUARY ACTIVITIES.
DE2963605D1 (en) Substituted 2-phenylamino-2-imidazolines, their acid addition salts, pharmaceutical compositions containing them and process for their preparation
DE2305517C3 (en) 2-Imino-13-dithiacyclobutanes, process for their preparation and warm-blooded protective agents against tick-insects containing them
DE2757431A1 (en) 5-FLUORURACIL DERIVATIVES AND AGENTS CONTAINING THEM
DE1190939B (en) Process for the preparation of new pi-allyl compounds of metals of III. to VIII. subgroup
DE2046203A1 (en) Polymeric tin mercaptides
CH513156A (en) Pyrroline cpds hypoglycaemics anti-diabetics
DE1768208A1 (en) High molecular organic tin compounds
DE2049814C3 (en) O, O-dialkyl-S-phenyl-dithiophosphoric acid ester, process for their preparation and their use
DE209609C (en)
DE2916991B2 (en) Process for the preparation of 1,4-bis (arylmethyl) piperazine compounds
DE1942013C3 (en) Thiazolo (thiono) phosphor (phosphonic) acid esters, process for their preparation and compositions containing them
DE124777T1 (en) DERIVATIVES OF 1,4-DIHYDROPYRIDINE.

Legal Events

Date Code Title Description
D2 Grant after examination
8364 No opposition during term of opposition